Matches in Wikidata for { <http://www.wikidata.org/entity/Q86170326> ?p ?o ?g. }
Showing items 1 to 87 of
87
with 100 items per page.
- Q86170326 description "clinical trial" @default.
- Q86170326 description "ensayu clínicu" @default.
- Q86170326 description "klinisch onderzoek" @default.
- Q86170326 description "клінічне випробування" @default.
- Q86170326 name "A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis (2011-09-20)" @default.
- Q86170326 name "A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis (2011-09-20)" @default.
- Q86170326 type Item @default.
- Q86170326 label "A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis (2011-09-20)" @default.
- Q86170326 label "A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis (2011-09-20)" @default.
- Q86170326 prefLabel "A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis (2011-09-20)" @default.
- Q86170326 prefLabel "A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis (2011-09-20)" @default.
- Q86170326 P1050 Q86170326-44DF9DEC-4B54-49A4-BBB2-5DF0F1DF7791 @default.
- Q86170326 P1050 Q86170326-E92F051B-8831-4A5D-89BC-122C7C6F787F @default.
- Q86170326 P1132 Q86170326-C8B54A09-2748-41A7-9562-78620E68757A @default.
- Q86170326 P1476 Q86170326-8C7A30F4-BE5F-4028-8EE6-78407EF4E89E @default.
- Q86170326 P17 Q86170326-011CBD78-D440-4B67-9827-526617D119A2 @default.
- Q86170326 P17 Q86170326-04F290D9-B494-49CD-AF00-0A0DB88860B8 @default.
- Q86170326 P17 Q86170326-0E5C7202-C145-4C9F-8859-6DF275E9CFF8 @default.
- Q86170326 P17 Q86170326-1299A766-35B5-4B17-AEAE-6668A5B149D3 @default.
- Q86170326 P17 Q86170326-15A60092-66AF-4321-92AF-86ED1FAF5EB7 @default.
- Q86170326 P17 Q86170326-1F483024-926E-496F-B9D8-9C5B17478034 @default.
- Q86170326 P17 Q86170326-28B054E4-3071-4048-91E7-E39A74B5A0F0 @default.
- Q86170326 P17 Q86170326-31BF0331-195C-4B93-B0A4-1FDC470761DB @default.
- Q86170326 P17 Q86170326-58B67657-04EC-4BC6-8640-BFF6D4F0FE2F @default.
- Q86170326 P17 Q86170326-64B25E3B-65DB-4B39-8E95-7E69B9E9264F @default.
- Q86170326 P17 Q86170326-6FE24B4F-1454-42A2-831B-5A05735D9E41 @default.
- Q86170326 P17 Q86170326-7412C14B-0916-4DD3-92CF-9B1F047990AC @default.
- Q86170326 P17 Q86170326-8DE56A83-DE55-457E-A1C8-6EED5BE21096 @default.
- Q86170326 P17 Q86170326-ABBCFA07-A6EA-457E-9945-04D25153688D @default.
- Q86170326 P17 Q86170326-B1CCA241-7170-4CAB-AA6B-C107F6785F44 @default.
- Q86170326 P17 Q86170326-B659ADC2-5900-43FC-80AC-36A258A861CB @default.
- Q86170326 P17 Q86170326-BD932D53-9F62-4C05-BDC5-F706615D018C @default.
- Q86170326 P17 Q86170326-C95AA5AB-E5F5-412C-B492-2B0E8BD2F91C @default.
- Q86170326 P17 Q86170326-CD418B33-4FBA-4AF5-ACA1-27814CF9405B @default.
- Q86170326 P17 Q86170326-F22B599E-0E31-4563-A225-3C80DFF145C8 @default.
- Q86170326 P17 Q86170326-F3450048-3492-4D4C-8CD2-49B8D12A46BE @default.
- Q86170326 P17 Q86170326-FF4E0187-5B78-4406-8456-057EF6CCBA36 @default.
- Q86170326 P2899 Q86170326-33327492-35A8-4495-AEE3-97968359DFE3 @default.
- Q86170326 P3098 Q86170326-B6DE1240-EA2F-4218-827D-D2CC78419128 @default.
- Q86170326 P31 Q86170326-FAEBB1DC-87ED-42B5-B74B-587696054E6F @default.
- Q86170326 P4135 Q86170326-1A19770E-EBC8-459E-862B-F2D4D9484DDF @default.
- Q86170326 P4844 Q86170326-724A12B9-B5EE-4022-9B32-7B1910F0FA0D @default.
- Q86170326 P4844 Q86170326-8685FD23-27A3-4BA9-997A-E8F08817801C @default.
- Q86170326 P4844 Q86170326-9D902217-C3D6-4E36-96B3-7939F7A85603 @default.
- Q86170326 P580 Q86170326-D922334E-672B-4AAA-BAE0-B62934B1FFC7 @default.
- Q86170326 P582 Q86170326-5031938A-C220-493F-B733-139DC9DA4F73 @default.
- Q86170326 P6099 Q86170326-8ACB9018-0A0E-49E9-8DAD-2AF166821C77 @default.
- Q86170326 P8363 Q86170326-543DA503-A249-4722-9E5B-A598161AE85F @default.
- Q86170326 P859 Q86170326-B5123BD8-C9C8-40DF-8B47-329D3B96250C @default.
- Q86170326 P1050 Q140067 @default.
- Q86170326 P1050 Q8277 @default.
- Q86170326 P1132 "+835" @default.
- Q86170326 P1476 "A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis" @default.
- Q86170326 P17 Q142 @default.
- Q86170326 P17 Q145 @default.
- Q86170326 P17 Q155 @default.
- Q86170326 P17 Q16 @default.
- Q86170326 P17 Q183 @default.
- Q86170326 P17 Q184 @default.
- Q86170326 P17 Q20 @default.
- Q86170326 P17 Q212 @default.
- Q86170326 P17 Q214 @default.
- Q86170326 P17 Q219 @default.
- Q86170326 P17 Q224 @default.
- Q86170326 P17 Q225 @default.
- Q86170326 P17 Q27 @default.
- Q86170326 P17 Q29 @default.
- Q86170326 P17 Q30 @default.
- Q86170326 P17 Q31 @default.
- Q86170326 P17 Q34 @default.
- Q86170326 P17 Q36 @default.
- Q86170326 P17 Q38 @default.
- Q86170326 P17 Q414 @default.
- Q86170326 P17 Q43 @default.
- Q86170326 P17 Q96 @default.
- Q86170326 P2899 "+18" @default.
- Q86170326 P3098 "NCT01412333" @default.
- Q86170326 P31 Q30612 @default.
- Q86170326 P4135 "+55" @default.
- Q86170326 P4844 Q188269 @default.
- Q86170326 P4844 Q2013780 @default.
- Q86170326 P4844 Q2450337 @default.
- Q86170326 P580 "2011-09-20T00:00:00Z" @default.
- Q86170326 P582 "2015-05-12T00:00:00Z" @default.
- Q86170326 P6099 Q42824827 @default.
- Q86170326 P8363 Q78089383 @default.
- Q86170326 P859 Q212646 @default.